NCT07054684RecruitingPhase 1
Study of BHV-1400 in IgA Nephropathy
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 27 Jun 2025
- Start date
- 30 Jul 2025
- Primary completion date
- Jul 2027
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Diseases
- Chronic kidney disease, IgA nephropathy
- NCT number
- NCT07054684
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- From 30 Jul 2025 to the primary completion date, Jul 2027
- 15 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
Other
- Any secondary IgAN
Who the study is looking for
- 1\. Participants must have biopsy-confirmed IgA Nephropathy
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.